Academic Journal
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
| العنوان: | Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin |
|---|---|
| المؤلفون: | Buda, G. (Gabriele), Ricci, D. (Deborah), Huang, C.C. (Chris), Favis, R. (Reyna), Cohen, N. (Nadine), Zhuang, S.H. (Sen), Harousseau, J-L. (Jean-Luc), Sonneveld, P. (Pieter), Bladé, J. (Joan), Orlowski, R.Z. (Robert) |
| المصدر: | Annals of Hematology vol. 89 no. 11, pp. 1133-1140 |
| سنة النشر: | 2010 |
| المجموعة: | RePub - Publications from Erasmus University, Rotterdam |
| مصطلحات موضوعية: | Bortezomib, MDR1, MRP1, Multiple myeloma, Pegylated liposomal doxorubicin, SNP |
| الوصف: | Single nucleotide polymorphisms (SNPs) in the multiple drug resistance protein 1 (MRP1) and P-glycoprotein 1 (MDR1) genes modulate their ability to mediate drug resistance. We therefore sought to retrospectively evaluate their influence on outcomes in relapsed and/or refractory myeloma patients treated with bortezomib or bortezomib with pegylated liposomal doxorubicin (PLD). The MRP1/R723Q polymorphism was found in five subjects among the 279 patient study population, all of whom received PLD∈+∈bortezomib. Its presence was associated with a longer time to progression (TTP; median 330 vs. 129 days; p∈=∈0.0008), progression-free survival (PFS; median 338 vs. 129 days; p∈=∈0.0006), and overall survival (p∈=∈0.0045). MDR1/3435(C∈>∈T), which was in Hardy-Weinberg equilibrium, showed a trend of association with PFS (p∈=∈0.0578), response rate (p∈=∈0.0782) and TTP (p∈=∈0.0923) in PLD∈+∈ bortezomib patients, though no correlation was found in the bortezomib arm. In a recessive genetic model, MDR1/3435 T was significantly associated with a better TTP (p∈=∈0.0405) and PFS (p∈=∈0.0186) in PLD∈+∈bortezomib patients. These findings suggest a potential role for MRP1 and MDR1 SNPs in modulating the long-term outcome of relapsed and/or refractory myeloma patients treated with PLD∈+∈bortezomib. Moreover, they support prospective studies to determine if such data could be used to tailor therapy to the genetic makeup of individual patients. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | http://repub.eur.nl/pub/28189; urn:hdl:1765/28189 |
| DOI: | 10.1007/s00277-010-0992-3 |
| الاتاحة: | http://repub.eur.nl/pub/28189 https://doi.org/10.1007/s00277-010-0992-3 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.3E5E6E8F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00277-010-0992-3 |
|---|